The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy

Figure 1

Abscopal effect of PDT with CAT@S/Ce6-CTPP/DPEG in combination with checkpoint blockade immunotherapy. (a) Schematic illustration to show the experimental design of combining PDT with anti-PD-L1 therapy (b–d). The tumor growth curves (b), average tumor weights at day 18 (c), and percentages of CTL infiltration at day 18 (d), for primary tumors (left) after various treatments indicated (e–g). The tumor growth curves (e), average tumor weights at day 18 (f), and percentages of CTL infiltration at day 18 (g), for nonirradiated tumors (right) after various treatments indicated. Data are presented as deviations (). (h) The IFN-γ levels in sera from mice detected at 7 days after various treatments. (i) Changes in body weight of mice during treatment. (j) A scheme indicating the mechanisms of combining PDT with anti-PD-L1 therapy. values in (b–h) were calculated by Turkey’s post-test (, , or ). The figure is adapted from [22] with permission of the copyright holder, American Chemical Society.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)